KRAS突变型肺癌作用机制与治疗策略的最新进展

doi:10.3969/j.issn.2095-1264.2023.06.07

首页 > 过刊浏览>2023年第6期 >702-708. DOI:10.3969/j.issn.2095-1264.2023.06.07

KRAS突变型肺癌作用机制与治疗策略的最新进展
DOI:
                        10.3969/j.issn.2095-1264.2023.06.07
                    
作者:
                        
                        
                    
作者单位:1.中南大学湘雅公共卫生学院 流行病与卫生统计系，湖南 长沙，410078;2.南华大学衡阳医学院 湖南省肿瘤医院研究生协作培养基地，湖南 衡阳，421001;3.吉首大学医学院 生物化学与免疫学系医学研究中心，湖南 吉首，416000;;4.湖南省肿瘤医院 头颈放疗二科;5.湖南省肿瘤医院 胸部放疗一科;6.肺胃肠内科，湖南 长沙，410013
作者简介:胡晓庆，女，硕士研究生，研究方向：流行病与卫生统计学。
通讯作者:张永昌，男，博士生导师，副主任医师，研究方向：肺胃肠道肿瘤
杨农，男，硕士生导师，主任医师，研究方向：肺胃肠道肿瘤。
中图分类号:R734.2
基金项目:

Recent advances in studies of KRAS mutated lung cancer

Author:

Affiliation:

1.Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, 410078, Hunan, China;2.Department of Medical Oncology, Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China;3.Department of Biochemistry and Immunology, College of Medical Science, Jishou University, Jishou, 416000, Hunan, China;4.Department of Head and Neck Radiotherapy II;5.Department of Thoracic Radiotherapy I;6.Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

肺癌是全球最常见的恶性肿瘤之一，KRAS是肺癌发生基因突变的重要位点。由于KRAS突变亚型中常缺乏药理学药物靶向的口袋，KRAS突变位点一直被认为是“不可成药”的靶点。本文主要概括了KRAS突变型肺癌的作用机制和KRAS成药所面临的困难，并对KRAS突变的治疗策略和耐药机制的最新进展进行阐述。

Abstract:

Lung cancer is one of the worldwide most common malignant tumors, and KRAS is an important gene mutation site in lung cancer. But KRAS has been considered "undruggable" due to the lack of pharmacologically targeted pockets in KRAS mutant subtypes. In this article, we mainly summarized the mechanism of KRAS mutation in lung cancer and the difficulties faced by KRAS drugs. Recent advances in treatment strategies and resistance mechanisms of KRAS-mutated lung cancer were also described.